Cargando…
LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas
Cases Presentations: Case 1: A 1-year-old boy with suprasellar pilocytic astrocytoma with previous history of shunting disfunction, treatment according vinblastine protocol due to anaphylactic reaction with carboplatin presented with ascites and necessity of ventricular-atrial shunt. Due to high pro...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165150/ http://dx.doi.org/10.1093/neuonc/noac079.355 |
_version_ | 1784720321272610816 |
---|---|
author | Dassi, Natália Cappellano, Andrea Costa, Marcos Watanabe, Rodrigo Soares, Carolina Silva, Frederico Almeida, Daniela Dastoli, Patricia Nicacio, Jardel Cavalheiro, Sérgio Saba, Nasjla |
author_facet | Dassi, Natália Cappellano, Andrea Costa, Marcos Watanabe, Rodrigo Soares, Carolina Silva, Frederico Almeida, Daniela Dastoli, Patricia Nicacio, Jardel Cavalheiro, Sérgio Saba, Nasjla |
author_sort | Dassi, Natália |
collection | PubMed |
description | Cases Presentations: Case 1: A 1-year-old boy with suprasellar pilocytic astrocytoma with previous history of shunting disfunction, treatment according vinblastine protocol due to anaphylactic reaction with carboplatin presented with ascites and necessity of ventricular-atrial shunt. Due to high protein cerebrospinal fluid (CSF) level (551mg/dl) he was submitted to external ventricular drainage and bevacizumab 10mg/kg was associated to his oncology treatment. After three cycles of bevacizumab, the patients’ CSF protein levels decreased dramatically 178 mg/dL, allowing the shunt procedure without complications and shorter hospital stay. Case 2: A ten-year-old boy with suprasellar pilocytic astrocytoma treated with three lines of chemotherapy showed tumor progression one year after the end of carboplatin-vincristine protocol and shunting disfunction. External ventricular drainage was performed, and the CSF showed 590mg/dl protein level. He was treated with vinblastine 6mg/m2 weekly and bevacizumab 10mg/kg each 14 days. After two cycles of bevacizumab, the protein level was 191mg/dl allowing another V-P shunt procedure. Discussion: Optic pathway gliomas frequently cause elevated cerebrospinal fluid protein concentrations leading to shunts occlusions and failures, necessity of external ventricular drainage and longtime hospitalization, implicating risk of serious infections. Bevacizumab is a monoclonal antibody with immunomodulatory and anti-vascular endothelial growth factor (VEGF) activities that has been used in combination with other chemotherapeutic agents such as irinotecan and vinblastine to treat low-grade gliomas and has been reported to decrease the CSF protein concentration.Final Comments: Bevacizumab treatment in patients with gliomas and high CSF protein levels seems effective in decreasing protein leakage from the vessels to the ventricles, thereby improving the scope for successful shunt placement. |
format | Online Article Text |
id | pubmed-9165150 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-91651502022-06-05 LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas Dassi, Natália Cappellano, Andrea Costa, Marcos Watanabe, Rodrigo Soares, Carolina Silva, Frederico Almeida, Daniela Dastoli, Patricia Nicacio, Jardel Cavalheiro, Sérgio Saba, Nasjla Neuro Oncol Low Grade Glioma Cases Presentations: Case 1: A 1-year-old boy with suprasellar pilocytic astrocytoma with previous history of shunting disfunction, treatment according vinblastine protocol due to anaphylactic reaction with carboplatin presented with ascites and necessity of ventricular-atrial shunt. Due to high protein cerebrospinal fluid (CSF) level (551mg/dl) he was submitted to external ventricular drainage and bevacizumab 10mg/kg was associated to his oncology treatment. After three cycles of bevacizumab, the patients’ CSF protein levels decreased dramatically 178 mg/dL, allowing the shunt procedure without complications and shorter hospital stay. Case 2: A ten-year-old boy with suprasellar pilocytic astrocytoma treated with three lines of chemotherapy showed tumor progression one year after the end of carboplatin-vincristine protocol and shunting disfunction. External ventricular drainage was performed, and the CSF showed 590mg/dl protein level. He was treated with vinblastine 6mg/m2 weekly and bevacizumab 10mg/kg each 14 days. After two cycles of bevacizumab, the protein level was 191mg/dl allowing another V-P shunt procedure. Discussion: Optic pathway gliomas frequently cause elevated cerebrospinal fluid protein concentrations leading to shunts occlusions and failures, necessity of external ventricular drainage and longtime hospitalization, implicating risk of serious infections. Bevacizumab is a monoclonal antibody with immunomodulatory and anti-vascular endothelial growth factor (VEGF) activities that has been used in combination with other chemotherapeutic agents such as irinotecan and vinblastine to treat low-grade gliomas and has been reported to decrease the CSF protein concentration.Final Comments: Bevacizumab treatment in patients with gliomas and high CSF protein levels seems effective in decreasing protein leakage from the vessels to the ventricles, thereby improving the scope for successful shunt placement. Oxford University Press 2022-06-03 /pmc/articles/PMC9165150/ http://dx.doi.org/10.1093/neuonc/noac079.355 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Low Grade Glioma Dassi, Natália Cappellano, Andrea Costa, Marcos Watanabe, Rodrigo Soares, Carolina Silva, Frederico Almeida, Daniela Dastoli, Patricia Nicacio, Jardel Cavalheiro, Sérgio Saba, Nasjla LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas |
title | LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas |
title_full | LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas |
title_fullStr | LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas |
title_full_unstemmed | LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas |
title_short | LGG-43. Reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas |
title_sort | lgg-43. reduction in the cerebrospinal fluid protein level after bevacizumab treatment in patients with optic pathway low-grade gliomas |
topic | Low Grade Glioma |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9165150/ http://dx.doi.org/10.1093/neuonc/noac079.355 |
work_keys_str_mv | AT dassinatalia lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT cappellanoandrea lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT costamarcos lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT watanaberodrigo lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT soarescarolina lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT silvafrederico lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT almeidadaniela lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT dastolipatricia lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT nicaciojardel lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT cavalheirosergio lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas AT sabanasjla lgg43reductioninthecerebrospinalfluidproteinlevelafterbevacizumabtreatmentinpatientswithopticpathwaylowgradegliomas |